BioMarker Strategies Awarded SBIR Grant to Develop Melanoma CDx | GenomeWeb

NEW YORK (GenomeWeb News) – BioMarker Strategies today announced it is being granted a $1.5 million Small Business Innovation Research Phase II award to further develop its companion diagnostic for melanoma.

The grant from the National Cancer Institute will go toward the Baltimore, Md.-based firm's refinement of its PathMap assay and ex vivo protocols developed under a Phase I SBIR contract. The new funding will also support validation of PathMap in human clinical samples, BioMarker Strategies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.